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Abstract Activation of p53 plays a central role in the cell’s
response to various stress signals. We investigated whether p53 is
activated upon disruption of actin microfilaments, caused by
cytochalasin D (CD). We show that treatment with CD leads to
accumulation of p53 in the cells and activation of p53-dependent
transcription. Treatment with CD led to arrest of G1-to-S
transition in cells retaining wild-type p53, while cells with
inactivated p53 showed partial rescue from it. CD also induces
apoptosis in p53+/+, but not in p533/3 cells. The obtained data
suggest that disruption of the actin microfilaments activates p53-
dependent pathways.
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1. Introduction
p53 plays a critical role in the control of cell growth [1^3].
Being one of the key components of the cell cycle control
network, p53 governs the cell’s reaction to multiple stress
signals such as DNA damage [4,5], inhibition of nucleic acid
synthesis [6,7], hypoxia [8] or overexpression of oncogenes [9].
p53 has the capacity to bind to speci¢c DNA sequences and
activate transcription of the genes whose promoters contain
such p53-responsive elements, so in response to various stress
signals p53 accumulates and enhances transcription of these
genes [1]. The p53 target genes are capable of facilitating
either G1 arrest (waf1, gadd45) or apoptosis (bax and a set
of redox-related PIG genes) in the cell a¡ected by the stress
conditions [10^14].
Among the conditions that result in activation of p53 are
disruption of microtubules and detachment of the cells from
the substrate [15,16]. These ¢ndings suggest that cytoskeleton
integrity, being vital to normal cell functioning, may also be
monitored by p53-dependent safeguard mechanisms. This, in
turn, allowed us to suggest that disruption of another cyto-
skeleton system ^ the actin micro¢lament network ^ might
also lead to activation of p53.
In this study we have investigated activation of p53 upon
treatment of cells with cytochalasin D (CD), which binds to
the barbed ends of actin ¢laments and inhibits both the dis-
sociation and the association of actin monomers at that end.
This leads to almost complete disorganization of the actin
network and accumulation of numerous foci of short actin
¢laments in the cells [17]. For this purpose several experimen-
tal models were used. To study the induction of p53 we used
primary and immortalized ¢broblasts retaining wild type (wt)
p53. Using two independent reporter genes we examined the
e¡ect of CD on the transcriptional activation ability of p53.
To address the e¡ect of p53 on growth and survival of the
cells treated with CD, we employed two distinct cell systems.
For induction of p53-dependent growth arrest we used im-
mortalized ¢broblast lines with di¡erent states of endogenous
p53. Finally, to con¢rm that the activated p53 is capable of
inducing apoptosis, we used a murine ¢broblast line which is
highly sensitive to p53-dependent apoptosis. We report here
that disruption of the actin micro¢laments with a speci¢c drug
activates p53 in the cells and may lead to p53-dependent
growth arrest or apoptosis.
2. Materials and methods
2.1. Cells
The cells used were: (i) normal rat embryo ¢broblasts (REF) at
passages 2^4 in vitro; (ii) a spontaneously immortalized REF52 rat
¢broblast cell line with functional wt p53 and its derivatives; (iii) the
REF52/GSE22 subline expressing genetic suppressor element #22
(GSE22), a short fragment of rat p53 cDNA corresponding to the
C-terminal fragment of p53 which inhibits p53 function via a domi-
nant negative mechanism [18]; and (iv) REF52/mdm-2/2, overexpress-
ing exogenous murine mdm-2 proto-oncogene. The mdm-2 product is
capable of binding to p53 and suppressing its transcriptional activa-
tion potential [19]. (v) For the chloramphenicol acetyltransferase
(CAT) assay, we used the REF52-CAT subline, constitutively express-
ing CAT under the control of the p53-responsive promoter from the
waf1 gene [20]. (vi) Murine wt-p53-positive immortalized ¢broblasts
(line 12(1)ConA) expressing bacterial L-galactosidase (L-gal) governed
by p53-responsive promoter [21] (kindly provided by Dr. M.V. Cher-
nov, Cleveland Clinic Foundation, Cleveland, OH, USA); (vii) im-
mortalized murine ¢broblasts (line 10(1)) which has a homozygous
deletion of the p53 gene [22]; (viii) E1A+ras-transformed mouse em-
bryo ¢broblasts (MEF) from p53+/+ and p533/3 mice. The p53+/+
cell line C8 is highly susceptible to apoptosis caused by various DNA
damaging agents while its p533/3 counterpart (A4) is highly resistant
to such treatments [23].
The cells were maintained in DMEM medium (all chemicals were
from Sigma, USA unless otherwise indicated) supplemented with 10%
fetal calf serum (Gibco-BRL, UK).
The doubling time of all the REF52 sublines, 12(1)ConA and 10(1)
cell lines was approximately 24 h; that of the C8 and A4 cell lines was
approximately 18 h.
2.2. CD treatment
CD was added to the culture medium at ¢nal concentrations of
0.25^0.4 Wm/ml 1^3 h after seeding. These doses are considered small,
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and their e¡ect is completely reversible [24]. The duration of treatment
is indicated for indivudal experiments.
2.3. Actin staining
Cells were seeded onto glass coverslips at 104 cell/cm2 and treated
with 0.25 Wg/ml CD for 72 h or left untreated. The coverslips were
washed with phosphate-bu¡ered saline (PBS), ¢xed with 4% para-
formaldehyde and permeabilized with 1% Triton X-100 in PBS. For
staining, cells were incubated with TRITC-labelled phalloidin in a
moist chamber.
2.4. Western blotting
Cells (107) were washed twice with cold PBS and lysed in 0.5 ml
bu¡er containing 20 mM HEPES (pH 7.6), 10 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 20% glycerol, 0.1% Triton X-100, 1 mM
dithiothreitol, 1 mM PMSF and 100 Wg/ml aprotinin. Nuclei obtained
by low-speed centrifugation were shaken for 45^60 min in the same
bu¡er supplemented with 500 mM NaCl. After centrifugation at
10 000 rpm for 10 min, nuclear extracts were separated by SDS-
PAGE. Proteins were transferred onto ECL membranes, probed
with p53-speci¢c monoclonal antibody PAb421, and developed using
ECL Western blotting kit (Amersham, UK).
2.5. CAT assay
The CAT assay was performed as described [19]. Quantitative
measurements of CAT activity were done by densitometry using Ul-
troscan XL (LKB, Sweden).
2.6. Analysis of 5-BrdU incorporation
Cells were seeded onto glass coverslips at 105 cells/cm2 and treated
with 0.25 Wg/ml CD for 72 h or left untreated. At the end of treatment
5-bromodeoxyuridine (5-BrdU) (Serva, USA) was added to the me-
dium at a ¢nal concentration of 10 mM for 5 h. The cells were washed
with PBS, ¢xed with 4% paraformaldehyde, permeabilized with 1%
Triton X-100 in bu¡er M (50 mM imidazole, 50 mM KCl, 0.5 mM
MgCl2, 0.1 mM EDTA, pH 6.8), containing 4% polyethylene glycol
Mr 40 000, and hydrolyzed with 4 N HCl. The cells were subsequently
incubated with anti-5-BrdU antibodies and TRITC-conjugated anti-
mouse IgG secondary antibodies (Chemicon, USA). To visualize all
nuclei, the cells were counterstained with DNA-speci¢c Hoechst dye
#33258 (Polysciences, USA).
2.7. L-Galactosidase staining
L-Gal staining was performed as described [20].
2.8. Apoptotic DNA ladder assay
The cells (1.5^3U106) were scraped into centrifuge tubes, washed
with PBS and pelleted by centrifugation. Cell pellets were then sus-
pended for 30 min on ice in 200 Wl of lysis bu¡er (20 mM Tris-HCl
pH 7.5, 10 mM EDTA, 0.2% Triton X-100). After centrifugation the
supernatant was collected, treated with proteinase K (0.1 mg/ml for
1.5 h at 37‡C) and extracted with phenol/chloroform and chloroform.
The DNA was precipitated by adding ammonium acetate (¢nal con-
centration 2 M) and ethanol, treated with RNase A (¢nal concentra-
tion 0.1 mg/ml) for 1.5 h and separated by electrophoresis in 1%
agarose.
3. Result
3.1. Cytochalasin D-induced disruption of actin cytoskeleton
causes increased transcriptional activity of p53
In control REF52 cells numerous thick straight bundles of
actin ¢laments were present. The comparatively low doses of
CD that we used disrupted these structures, and in CD-treated
cells actin was accumulated in multiple aster-like aggregates of
short ¢laments. The actin structures in REF52/GSE22 and
REF52/mdm-2/2 cells were similar to those found in REF52
cells (Fig. 1).
To test whether p53 accumulates in the cells upon applica-
tion of CD, we performed Western blot analysis of nuclear
lysates of the cells. As demonstrated in Fig. 2a, primary REFs
as well as immortalized REF52 ¢broblasts showed increased
intracellular content of wt p53 after treatment with CD for 24
and 48 h.
To investigate directly whether increased amounts of p53
correlate with its higher function activity, we tested transcrip-
tional activation by p53 of two reporter genes governed by
p53-responsive promoters. Treatment of REF52-CAT cells
bearing the CAT reporter construct with CD at concentra-
tions of 0.2^1 Wg/ml resulted in an approximately six-fold
activation of the enzyme (Fig. 2b). CD applied at concentra-
tions of 0.4^0.8 Wg/ml produced maximal activation of p53.
We also used the L-gal reporter system which allowed us to
monitor p53 activity in individual cells. 12(1)ConA cells were
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Fig. 1. Control (a) and CD-treated (b) REF52 cells stained for ac-
tin. CD transforms bundles of actin ¢laments into actin aggregates
distributed irregularly within the cell. Bar, 50 Wm.
Fig. 2. CD causes activation of p53. a: Western blot of nuclear ly-
sates shows accumulation of p53 in REF and REF52 cells after
treatment with CD at 1 Wg/ml for 24 and 48 h. In p53-de¢cient
10(1) cells no protein was detected in either control or CD-treated
cultures. b: CAT assay of REF52-CAT cells expressing p53-respon-
sible reporter. The cells were treated with the drug at the indicated
concentrations for 36 h. c, d: Control (c) and CD-treated (d)
12(1)ConA cells stained for L-gal reporter activity. c: no visible
staining. d: two L-gal-positive cells in the center of the cluster. The
majority of the cells contain two nuclei. Bar, 50 Wm.
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treated with 0.4 Wg/ml CD for 72 h, and then stained for L-gal
activity. CD treatment led to an overall increase in staining
(51.3% of the cells stained positively compared to 2.4% in
control), although the degree of staining varied considerably
between individual cells (Fig. 2c,d).
3.2. CD treatment leads to inhibition of S-phase entry
For further demonstration of enhanced p53 activity upon
CD treatment we tested the cellular e¡ects of p53 activation.
For this purpose, we monitored the incorporation of 5-BrdU
into cellular DNA in the unsynchronized REF52 cell line and
in its sublines REF52/GSE22 and REF52/mdm-2/2. Untreated
cells did not di¡er signi¢cantly in their ability to enter S phase
^ approximately 50% of the cells of all the lines stained pos-
itively for 5-BrdU after incubation of 2-day-old cultures with
5-BrdU for 5 h. Treatment with CD caused a reduction in 5-
BrdU-positive cell number in all REF52 sublines. The e¡ect of
the drug was seen within 24 h and reached its peak at 72 h
when S-phase entry in REF52 cells was practically blocked.
Upon similar treatment the sublines with blocked p53 func-
tion continued cycling, although more slowly compared to the
control (Fig. 3a). After 72 h of CD treatment the cells often
formed additional nuclei as a result of CD-blocked cytokine-
sis. However, we did not observe any correlation between the
cell’s ability to enter S phase and the number of nuclei. Inter-
estingly, the percentage of 5-BrdU-positive cells after CD
treatment was two-fold higher in REF52/mdm-2/2 than in
REF52/GSE22 cell line (Fig. 3a). Recent evidence reveals in-
teraction between mdm-2 and Rb proteins leading to inhib-
ition of Rb growth regulatory function [25]. In this light our
results may be interpreted as a cumulative e¡ect of inactivat-
ing both p53 and Rb by mdm-2.
To determine if G1-to-S transition might be arrested in CD-
treated cells, we analyzed the incorporation of BrdU into
synchronized cell cultures treated with CD. The cells were
synchronized by 48 h serum withdrawal, after which, in 1 h
after addition of the serum to the cultures, CD and BrdU
were added to the cells, and the cultures were incubated fur-
ther for 15 h.
Fifteen hours is less than the doubling time for the cell lines
we used (approximately 24 h), and the majority of the cells
(95% of the REF52 and REF52/GSE22 and 90% for
12(1)ConA and 10(1)) remained mononuclear. When CD
was added to the synchronized cultures, p53+/+ cells in
both pairs (REF52 and 12(1)ConA lines) did not enter S
phase during the 15 h of the treatment, while the cells lacking
p53 activity (REF52/GSE22 and 10(1) lines) were not arrested
and commenced DNA synthesis (Fig. 3b,c). These results al-
lowed us to suggest that p53 was activated shortly after addi-
tion of CD to the cultures, and that the p53-mediated cell
cycle arrest occurred immediately thereafter, in the G1 phase.
3.3. Induction of apoptosis by CD is dependent on the p53 state
Another known e¡ect of p53 activation is induction of
apoptosis. However, the choice between p53-dependent cell
cycle arrest and apoptosis depends largely on the cell type.
To check whether treatment with CD might in fact induce
p53-dependent apoptosis, we used MEFs transformed with
E1A plus ras oncogenes, which undergo apoptosis rather
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Fig. 3. CD leads to p53-dependent growth arrest in cells. a: Histo-
gram showing the percentage of 5-BrdU-positive REF52 (p53+/+),
REF52/GSE22 and REF52/mdm-2/2 (blocked p53 function) cells in
control cultures (gray) and after treatment with CD for 72 h
(black). For each point, more than 500 cells were scored. b, c: His-
togram showing the percentage of 5-BrdU-positive cells in synchro-
nized culture of REF52 and REF52/GSE22 (c) and 12(1)ConA
(p53+/+) and 10(1) (p533/3) (d) after treatment with CD for 15 h.
Fig. 4. CD leads to p52-dependent apoptosis. Growth and apoptosis
rates of C8 (p53+/+) (a) and A4 (p533/3) (b) cells in control (open
squares/triangles) and during CD treatment (¢lled squares/triangles).
Cell quantitation was done by counting the nuclei of the cells at-
tached to the coverslips. The nuclei were stained with £uorescent
Hoechst dye #33258. In the course of the CD treatment, p533/3
cells continue to proliferate, although the rate of proliferation de-
creases. The number of p53+/+ cells decreases rapidly. c: Electro-
phoresis of low molecular weight DNA isolated from C8 p53+/+
(lanes 1^3) and A4 p533/3 cells (lanes 4^6). Numbers indicate the
duration of the CD treatment (hours). The apoptotic DNA ladder
is visible in the C8 p53+/+ cells growing in the presence of CD for
12 and 24 h (lanes 2 and 3) while only traces of degraded DNA are
present in A4 p533/3 cells after CD treatment for 24 h.
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than growth arrest upon activation of p53 [23]. p533/3
MEFs transformed with the same oncogenes served as a neg-
ative control.
In untreated cells of both lines actin ¢laments were scarce
and relatively thin. CD caused complete degradation of the
¢laments and accumulation of the small actin aggregates in
the cytoplasm.
The control p53+/+ C8 and p533/3 A4 cell lines had sim-
ilar growth characteristics ; however, upon application of CD
the di¡erence became dramatic. Since CD leads to the appear-
ance of multinuclear cells in culture, we monitored the num-
ber of nuclei of the cells attached to the substrate per unit
area, rather than the cell number. In the course of the treat-
ment the C8 p53+/+ cells readily underwent apoptosis, and by
48 h the number of nuclei remaining on the substrate consti-
tuted 6.3% of their number at 0 h (Fig. 4a). Most of those
nuclei were stained picnotically. The number of nuclei of the
A4 p533/3 cells decreased from 100% at 0 h to 55.4% at 48 h
(Fig. 4b). By 48 h most of the p533/3 cells contained 2^4
nuclei, and they retained their size and shape, showing no
signs of apoptosis.
Apoptosis is usually accompanied by internucleosomal
cleavage of genomic DNA. After treatment with CD, the
C8 p53+/+ cells contained large amounts of low molecular
weight DNA migrating on agarose gel as a characteristic
apoptotic ladder. The DNA fragmentation was seen as early
as 12 h after application of the drug. In contrast, the A4
p533/3 cells contained only traces of degraded DNA after
CD treatment for 24 h (Fig. 4c).
4. Discussion
In this work we have shown that in response to CD cells
accumulate functionally active p53 and consequently undergo
cell cycle arrest or apoptosis. The cells with deleted p53, or
where the p53 function is blocked by either introduction of a
dominant negative GSE or overexpression of mdm-2, failed to
undergo growth arrest and formed additional nuclei in the
presence of CD. We also showed that cells expressing endog-
enous wt p53, which are highly prone to p53-mediated apop-
tosis, react to CD by undergoing apoptosis. In contrast, sim-
ilar p533/3 cells did not die by apoptosis, but became
multinuclear.
Earlier studies reported that low doses of cytochalasin in-
duce cell cycle arrest in G0/G1 but not in G2 phase [26^28]. In
this work we showed that this arrest is mediated by p53.
When the cells were synchronized in G0 by serum withdrawal
and then treated with CD for 15 h, cells lacking functional
p53 or with p53 lost through mutations passed G1 phase and
commenced DNA synthesis. In contrast, the cells containing
wt p53 were arrested in G1 and did not enter S phase.
CD impairs the cell’s ability to undergo cytokinesis, yet the
mitotic spindle remains intact. This means essentially normal
segregation of chromosomes and ¢lial nucleus formation.
Therefore, treatment of the cells with CD results in formation
of multinuclear cells in culture [26,29,30]. In our recent study
we have shown that spontaneously derived or colcemid-in-
duced micronuclei cause activation of p53 with strong depend-
ence on their number [31]. Considering this the appearance of
additional nuclei in CD-treated cells seems a plausible candi-
date for the signal triggering p53 activation. However, 15-h
incubation with CD was not long enough for most cells to
complete the cycle and pass through mitosis, so the majority
(90^95%) of cells stayed mononuclear. Thus, this experiment
allowed us to conclude that the CD-induced p53 activation is
independent of the nucleus number.
Therefore, it is likely that activation of p53 in CD-treated
cultures is due to some consequence of actin cytoskeleton
disintegration in both mononuclear and multinuclear cells.
In particular, disruption of actin ¢laments by CD results in
a decrease of cortical tension in the cell that might be accom-
panied by a decrease in DNA synthesis [32]. Another possi-
bility is that p53 activation is a result of shortening of focal
adhesions associated with poorer cell spreading and attach-
ment. This e¡ect of low doses of CD is well known [24,33].
The latter hypothesis is consistent with the observation that
detachment from the substrate causes apoptosis in the C8
p53+/+ cell line [16], which was also used by us.
Breaking the actin ¢lament network with a speci¢c drug
causes p53 activation and consequent growth arrest or apop-
tosis. On the whole, our experiments stress the importance of
the actin cytoskeleton in regulation of cell proliferation.
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